Precision BioSciences, Inc. (DTIL)Healthcare | Biotechnology | Durham, United States | NasdaqCM
7.78 USD
-0.62
(-7.381%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 7.85 +0.07 (0.900%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:04 a.m. EDT
The long-term investment case is effectively broken. Despite a 'strong buy' analyst recommendation driven by potential clinical data, the company's price history tells a different story: a catastrophic multi-year decline where the stock has lost over 98% of its value. The market has punished the business repeatedly, with four consecutive years of negative annual returns, signaling that investors see no sustainable path to recovery. This is not a value trap; it is a deteriorating asset where the balance sheet is strained by negative free cash flow and the business model has failed to generate returns on equity or assets for years. The recent price surge is likely a reaction to specific trial data, but without a proven track record of profitability or consistent growth, this remains a high-risk gamble rather than a solid investment. On the short end, the recent rally has created some local resistance, and the lack of a clear trend reversal keeps the immediate outlook neutral-to-bearish. There is no dividend to provide any cushion. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.091884 |
| MSTL | 0.096969 |
| AutoARIMA | 0.097022 |
| AutoETS | 0.097022 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 0.62 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.102 |
| Excess Kurtosis | -0.58 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 62.043 |
| Revenue per Share | 2.213 |
| Market Cap | 214,740,096 |
| Forward P/E | -4.18 |
| Beta | 1.23 |
| Profit Margins | -117.04% |
| Website | https://precisionbiosciences.com |
As of Aug. 22, 2026, 5:04 a.m. EDT: Speculators are positioning defensively with heavy put volume at the $2.5 strike, suggesting a fear of further downside or a hedge against volatility. Call interest is concentrated near-the-money and slightly out-of-the-money, indicating a desire for modest gains rather than a speculative moonshot. The implied volatility is elevated relative to deep OTM strikes, reflecting uncertainty around the upcoming catalysts and trial results.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.67999995 |
| Address1 | 302 East Pettigrew St. |
| Address2 | Suite A-100 |
| All Time High | 710.1 |
| All Time Low | 3.53 |
| Ask | 7.84 |
| Ask Size | 1 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 306,760 |
| Average Daily Volume3 Month | 423,932 |
| Average Volume | 423,932 |
| Average Volume10Days | 306,760 |
| Beta | 1.229 |
| Bid | 7.81 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | 1.713 |
| City | Durham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.78 |
| Current Ratio | 12.822 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 8.43 |
| Day Low | 7.72 |
| Debt To Equity | 62.043 |
| Display Name | Precision BioSciences |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,622,600 |
| Earnings Timestamp Start | 1,793,622,600 |
| Ebitda | -35,148,000 |
| Ebitda Margins | -0.78011 |
| Enterprise To Ebitda | -4.418 |
| Enterprise To Revenue | 3.447 |
| Enterprise Value | 155,292,096 |
| Eps Current Year | -3.86667 |
| Eps Forward | -1.86 |
| Eps Trailing Twelve Months | -1.22 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 480 393 5553 |
| Fifty Day Average | 7.7694 |
| Fifty Day Average Change | 0.01060009 |
| Fifty Day Average Change Percent | 0.0013643383 |
| Fifty Two Week Change Percent | 67.99999 |
| Fifty Two Week High | 9.62 |
| Fifty Two Week High Change | -1.8399997 |
| Fifty Two Week High Change Percent | -0.19126816 |
| Fifty Two Week Low | 3.53 |
| Fifty Two Week Low Change | 4.25 |
| Fifty Two Week Low Change Percent | 1.203966 |
| Fifty Two Week Range | 3.53 - 9.62 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,553,779,800,000 |
| Float Shares | 25,456,637 |
| Forward Eps | -1.86 |
| Forward P E | -4.182796 |
| Free Cashflow | -16,252,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 67 |
| Fullday Change | -0.619999 |
| Fullday Change Percent | -7.38095 |
| Fullday Price | 7.85 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 1.0 |
| Gross Profits | 45,055,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.080249995 |
| Held Percent Institutions | 0.68668 |
| Implied Shares Outstanding | 27,601,554 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,707,868,800 |
| Last Split Factor | 1:30 |
| Long Business Summary | Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. |
| Long Name | Precision BioSciences, Inc. |
| Market | us_market |
| Market Cap | 214,740,096 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_41018856 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -53,617,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 231,577,038 |
| Number Of Analyst Opinions | 5 |
| Open | 8.37 |
| Operating Cashflow | -51,899,000 |
| Operating Margins | -0.80779 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 919 314 5512 |
| Post Market Change | 0.069999695 |
| Post Market Change Percent | 0.89973897 |
| Post Market Price | 7.85 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 8.4 |
| Price Eps Current Year | -2.0120673 |
| Price Hint | 2 |
| Price To Book | 4.5417395 |
| Price To Sales Trailing12 Months | 4.7661767 |
| Profit Margins | -1.17039 |
| Quick Ratio | 12.262 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.619999 |
| Regular Market Change Percent | -7.38095 |
| Regular Market Day High | 8.43 |
| Regular Market Day Low | 7.72 |
| Regular Market Day Range | 7.72 - 8.43 |
| Regular Market Open | 8.37 |
| Regular Market Previous Close | 8.4 |
| Regular Market Price | 7.78 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 222,325 |
| Return On Assets | -0.19372 |
| Return On Equity | -1.35146 |
| Revenue Per Share | 2.213 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 27,601,554 |
| Shares Percent Shares Out | 0.087 |
| Shares Short | 2,401,307 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,384,495 |
| Short Name | Precision BioSciences, Inc. |
| Short Percent Of Float | 0.089099996 |
| Short Ratio | 8.29 |
| Source Interval | 15 |
| State | NC |
| Symbol | DTIL |
| Target High Price | 60.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 29.4 |
| Target Median Price | 20.0 |
| Total Cash | 87,549,000 |
| Total Cash Per Share | 3.172 |
| Total Debt | 28,101,000 |
| Total Revenue | 45,055,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.22 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.103175 |
| Two Hundred Day Average Change | 1.676825 |
| Two Hundred Day Average Change Percent | 0.27474633 |
| Type Disp | Equity |
| Volume | 222,325 |
| Website | https://precisionbiosciences.com |
| Zip | 27,701 |